This study is a 2 period, open label study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 3 months and 12 years. Dasiglucagon will be administered as a subcutaneous infusion. To be eligible, subjects are to have at least 3 or more hypoglycemic events a week, and are to have undergone a pancreatectomy for hyperinsulinism or are being treated with a non-surgical approach, because they were not eligible for pancreatic surgery.
Congenital Hyperinsulinism Center Clinical Studies
1 - 3 of 3
Our team is working on a study to better understand neurological problems, including seizures and developmental delays, that occur in many individuals with HI /HA syndrome. The study involves a one day visit to The Children’s Hospital of Philadelphia and The University of Pennsylvania for a specialized magnetic resonance imaging scan (MRI) of the brain, an electroencephalogram (EEG), blood draw, and completion of questionnaires to evaluate development and behavior. The entire study visit is expected to take about four hours. If you are interested in learning more, please contact us at HIResearch@email.chop.edu.
Our team is working on a study to see if children with HI/HA Syndrome tolerate Vitamin E supplementation. This is an experimental, non-FDA approved use of Vitamin E which will lead to further studies to evaluate if Vitamin E can be used as a treatment for HI/HA. The study involves taking Vitamin E once a day for two weeks at home, completing a tolerability questionnaires, and two, one-day visits to the CHOP outpatient Center for Human Phenomic Science (one visit before and one visit after taking the Vitamin E supplement for two weeks). During each study visit, fasting oral protein tolerance will be performed and blood samples will be drawn. If you're interested in learning more, please contact us at email@example.com or firstname.lastname@example.org.